These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10540322)

  • 1. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.
    Firat H; Garcia-Pons F; Tourdot S; Pascolo S; Scardino A; Garcia Z; Michel ML; Jack RW; Jung G; Kosmatopoulos K; Mateo L; Suhrbier A; Lemonnier FA; Langlade-Demoyen P
    Eur J Immunol; 1999 Oct; 29(10):3112-21. PubMed ID: 10540322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
    Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
    J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S; Wang F; He X; He Y; Li D; Sun S
    Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice.
    Firat H; Cochet M; Rohrlich PS; Garcia-Pons F; Darche S; Danos O; Lemonnier FA; Langlade-Demoyen P
    Int Immunol; 2002 Aug; 14(8):925-34. PubMed ID: 12147629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.
    Alexander J; Oseroff C; Sidney J; Sette A
    Hum Immunol; 2003 Feb; 64(2):211-23. PubMed ID: 12559623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
    Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
    J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
    Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
    Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
    Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
    Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.
    BenMohamed L; Krishnan R; Longmate J; Auge C; Low L; Primus J; Diamond DJ
    Hum Immunol; 2000 Aug; 61(8):764-79. PubMed ID: 10980387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
    Colombetti S; Fagerberg T; Baumgärtner P; Chapatte L; Speiser DE; Rufer N; Michielin O; Lévy F
    J Immunol; 2006 Jun; 176(11):6560-7. PubMed ID: 16709813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
    Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
    J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes.
    Dadaglio G; Morel S; Bauche C; Moukrim Z; Lemonnier FA; Van Den Eynde BJ; Ladant D; Leclerc C
    Int Immunol; 2003 Dec; 15(12):1423-30. PubMed ID: 14645151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization.
    Loirat D; Lemonnier FA; Michel ML
    J Immunol; 2000 Oct; 165(8):4748-55. PubMed ID: 11035120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes.
    Cheuk E; D'Souza C; Hu N; Liu Y; Lang H; Chamberlain JW
    J Immunol; 2002 Nov; 169(10):5571-80. PubMed ID: 12421934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.
    Snyder JT; Belyakov IM; Dzutsev A; Lemonnier F; Berzofsky JA
    J Virol; 2004 Jul; 78(13):7052-60. PubMed ID: 15194781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
    Tine JA; Firat H; Payne A; Russo G; Davis SW; Tartaglia J; Lemonnier FA; Demoyen PL; Moingeon P
    Vaccine; 2005 Jan; 23(8):1085-91. PubMed ID: 15620483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design.
    Wada H; Shimizu A; Osada T; Tanaka Y; Fukaya S; Sasaki E
    PLoS One; 2018; 13(7):e0199249. PubMed ID: 29969453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.